Pimasertib (PIM) versus dacarbazine (DTIC) in patients (pts) with cutaneous NRAS melanoma: a controlled, open-label phase II trial with crossover
Célèste Lebbé(Inserm), Brigitte Dréno(Nantes Université), Filippo de Braud(University of Milan), Joseph Kerger(Institut Jules Bordet), Virginia Ferraresi(Cancer Institute (WIA)), Thierry Lesimple, P. Vasey(Wesley Hospital), Enrique Espinosa(Hospital Universitario La Paz), Armin Schueler(Merck KGaA, Darmstadt (Germany)), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Andriy Markivskyy(Merck KGaA, Darmstadt (Germany)), Jean‐Jacques Grob(Aix-Marseille Université), B. Guillot(Université de Montpellier), Robert M. Conry(University of Alabama), Carmen Loquai(Johannes Gutenberg University Mainz), L. Thomas(University of Liverpool), Caroline Robert(Institut Gustave Roussy), Claus Garbe(University of Tübingen), Wim H.J. Kruit(Erasmus MC), R. Isaacs(Palmerston North Hospital)
Cited by 14
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k